{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T00:14:38Z","timestamp":1790727278290,"version":"4.1.0"},"reference-count":46,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T00:00:00Z","timestamp":1588723200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Leukemia"],"published-print":{"date-parts":[[2020,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Patients with multiple myeloma who have relapsed after or become refractory to lenalidomide in early treatment lines represent a clinically important population in need of effective therapies. The safety and efficacy of pomalidomide, low-dose dexamethasone, and daratumumab was evaluated in lenalidomide-pretreated patients with relapsed or refractory multiple myeloma (RRMM) after one to two prior treatment lines in the phase 2 MM-014 study. Patients received pomalidomide 4\u2009mg daily from days 1\u201321 and dexamethasone 40\u2009mg weekly (28-day cycles). Daratumumab 16\u2009mg\/kg was administered per label. Primary endpoint was overall response rate (ORR); secondary endpoints included progression-free survival (PFS) and safety. Per protocol, all patients (<jats:italic>N<\/jats:italic>\u2009=\u2009112) had received lenalidomide in their most recent prior regimen (75.0% lenalidomide refractory). ORR was 77.7% (76.2% in lenalidomide-refractory patients); median follow-up was\u00a017.2 months. Median PFS was not reached (1-year PFS rate 75.1%). The most common hematologic grade 3\/4 treatment-emergent adverse event was neutropenia (62.5%). Grade 3\/4 infections were reported in 31.3% of patients, including 13.4% with grade 3\/4 pneumonia. These results demonstrate the safety and efficacy of pomalidomide-based therapy as early as second line in patients with RRMM, even immediately after lenalidomide failure, indicating that switching from the immunomodulatory agent class is not necessary.<\/jats:p>","DOI":"10.1038\/s41375-020-0813-1","type":"journal-article","created":{"date-parts":[[2020,5,6]],"date-time":"2020-05-06T11:03:33Z","timestamp":1588763013000},"page":"3286-3297","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":77,"title":["Pomalidomide, dexamethasone, and daratumumab in relapsed refractory multiple myeloma after lenalidomide treatment"],"prefix":"10.1038","volume":"34","author":[{"given":"David S.","family":"Siegel","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gary J.","family":"Schiller","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christy","family":"Samaras","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Sebag","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jesus","family":"Berdeja","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siddhartha","family":"Ganguly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey","family":"Matous","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Seet","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giampaolo","family":"Talamo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mirelis","family":"Acosta-Rivera","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael","family":"Bar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Quick","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bertrand","family":"Anz","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Gustavo","family":"Fonseca","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donna","family":"Reece","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"William E.","family":"Pierceall","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Weiyuan","family":"Chung","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Faiza","family":"Zafar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amit","family":"Agarwal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nizar J.","family":"Bahlis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2020,5,6]]},"reference":[{"key":"813_CR1","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1111\/bjh.14780","volume":"179","author":"P Moreau","year":"2017","unstructured":"Moreau P, de Wit E. Recent progress in relapsed multiple myeloma therapy: implications for treatment decisions. Br J Haematol. 2017;179:198\u2013218.","journal-title":"Br J Haematol"},{"key":"813_CR2","doi-asserted-by":"crossref","first-page":"963","DOI":"10.1182\/blood-2017-03-726703","volume":"130","author":"JL Harousseau","year":"2017","unstructured":"Harousseau JL, Attal M. How I treat first relapse of myeloma. Blood. 2017;130:963\u201373.","journal-title":"Blood"},{"key":"813_CR3","doi-asserted-by":"crossref","first-page":"396","DOI":"10.3324\/haematol.2015.129189","volume":"101","author":"P Sonneveld","year":"2016","unstructured":"Sonneveld P, Broijl A. Treatment of relapsed and refractory multiple myeloma. Haematologica. 2016;101:396\u2013406.","journal-title":"Haematologica"},{"key":"813_CR4","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1111\/bjh.14193","volume":"175","author":"MS Raab","year":"2016","unstructured":"Raab MS, Cavo M, Delforge M, Driessen C, Fink L, Flinois A, et al. Multiple myeloma: practice patterns across Europe. Br J Haematol. 2016;175:66\u201376.","journal-title":"Br J Haematol"},{"key":"813_CR5","doi-asserted-by":"crossref","DOI":"10.1038\/s41408-019-0200-1","volume":"9","author":"P Moreau","year":"2019","unstructured":"Moreau P, Zamagni E, Mateos M-V. Treatment of patients with multiple myeloma progressing on frontline-therapy with lenalidomide. Blood Cancer J. 2019;9:38.","journal-title":"Blood Cancer J"},{"key":"813_CR6","doi-asserted-by":"crossref","first-page":"621","DOI":"10.1056\/NEJMoa1505654","volume":"373","author":"S Lonial","year":"2015","unstructured":"Lonial S, Dimopoulos M, Palumbo A, White D, Grosicki S, Spicka I, et al. Elotuzumab therapy for relapsed or refractory multiple myeloma. N Engl J Med. 2015;373:621\u201331.","journal-title":"N Engl J Med"},{"key":"813_CR7","doi-asserted-by":"crossref","first-page":"142","DOI":"10.1056\/NEJMoa1411321","volume":"372","author":"AK Stewart","year":"2015","unstructured":"Stewart AK, Rajkumar SV, Dimopoulos MA, Masszi T, \u0160pi\u010dka I, Oriol A, et al. Carfilzomib, lenalidomide, and dexamethasone for relapsed multiple myeloma. N Engl J Med. 2015;372:142\u201352.","journal-title":"N Engl J Med"},{"key":"813_CR8","doi-asserted-by":"crossref","first-page":"1621","DOI":"10.1056\/NEJMoa1516282","volume":"374","author":"P Moreau","year":"2016","unstructured":"Moreau P, Masszi T, Grzasko N, Bahlis NJ, Hansson M, Pour L, et al. Oral ixazomib, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;374:1621\u201334.","journal-title":"N Engl J Med"},{"key":"813_CR9","doi-asserted-by":"crossref","first-page":"1319","DOI":"10.1056\/NEJMoa1607751","volume":"375","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Oriol A, Nahi H, San-Miguel J, Bahlis NJ, Usmani SZ, et al. Daratumumab, lenalidomide, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:1319\u201331.","journal-title":"N Engl J Med"},{"key":"813_CR10","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1038\/bmt.2015.307","volume":"51","author":"RF Cornell","year":"2016","unstructured":"Cornell RF, Kassim AA. Evolving paradigms in the treatment of relapsed\/refractory multiple myeloma: increased options and increased complexity. Bone Marrow Transpl. 2016;51:479\u201391.","journal-title":"Bone Marrow Transpl"},{"key":"813_CR11","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1111\/bjh.14213","volume":"175","author":"K Yong","year":"2016","unstructured":"Yong K, Delforge M, Driessen C, Fink L, Flinois A, Gonzalez-McQuire S, et al. Multiple myeloma: patient outcomes in real-world practice. Br J Haematol. 2016;175:252\u201364.","journal-title":"Br J Haematol"},{"key":"813_CR12","doi-asserted-by":"crossref","first-page":"e354","DOI":"10.1038\/bcj.2015.66","volume":"5","author":"CC Bjorklund","year":"2015","unstructured":"Bjorklund CC, Lu L, Kang J, Hagner PR, Havens CG, Amatangelo M, et al. Rate of CRL4(CRBN) substrate Ikaros and Aiolos degradation underlies differential activity of lenalidomide and pomalidomide in multiple myeloma cells by regulation of c-Myc and IRF4. Blood Cancer J. 2015;5:e354.","journal-title":"Blood Cancer J"},{"key":"813_CR13","doi-asserted-by":"crossref","first-page":"2326","DOI":"10.1038\/leu.2012.119","volume":"26","author":"A Lopez-Girona","year":"2012","unstructured":"Lopez-Girona A, Mendy D, Ito T, Miller K, Gandhi AK, Kang J, et al. Cereblon is a direct protein target for immunomodulatory and antiproliferative activities of lenalidomide and pomalidomide. Leukemia. 2012;26:2326\u201335.","journal-title":"Leukemia"},{"key":"813_CR14","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1038\/leu.2014.238","volume":"29","author":"EM Ocio","year":"2014","unstructured":"Ocio EM, Fern\u00e1ndez-L\u00e1zaro D, San-Segundo L, L\u00f3pez-Corral L, Corchete LA, Guti\u00e9rrez NC, et al. In vivo murine model of acquired resistance in myeloma reveals differential mechanisms for lenalidomide and pomalidomide in combination with dexamethasone. Leukemia. 2014;29:705\u201314.","journal-title":"Leukemia"},{"key":"813_CR15","doi-asserted-by":"crossref","first-page":"4042","DOI":"10.1182\/blood-2014-11-611426","volume":"125","author":"K Sehgal","year":"2015","unstructured":"Sehgal K, Das R, Zhang L, Verma R, Deng Y, Kocoglu M, et al. Clinical and pharmacodynamic analysis of pomalidomide dosing strategies in myeloma: impact of immune activation and cereblon targets. Blood. 2015;125:4042\u201351.","journal-title":"Blood"},{"key":"813_CR16","doi-asserted-by":"crossref","first-page":"497","DOI":"10.1182\/blood-2016-02-700872","volume":"128","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Palumbo A, Corradini P, Cavo M, Delforge M, Di Raimondo F, et al. Safety and efficacy of pomalidomide plus low-dose dexamethasone in STRATUS (MM-010): a phase 3b study in refractory multiple myeloma. Blood. 2016;128:497\u2013503.","journal-title":"Blood"},{"key":"813_CR17","doi-asserted-by":"crossref","first-page":"1968","DOI":"10.1182\/blood-2012-09-452375","volume":"121","author":"X Leleu","year":"2013","unstructured":"Leleu X, Attal M, Arnulf B, Moreau P, Traulle C, Marit G, et al. Pomalidomide plus low-dose dexamethasone is active and well tolerated in bortezomib and lenalidomide\u2013refractory multiple myeloma: Intergroupe Francophone du My\u00e9lome 2009-02. Blood. 2013;121:1968\u201375.","journal-title":"Blood"},{"key":"813_CR18","doi-asserted-by":"crossref","first-page":"1826","DOI":"10.1182\/blood-2013-11-538835","volume":"123","author":"PG Richardson","year":"2014","unstructured":"Richardson PG, Siegel DS, Vij R, Hofmeister CC, Baz R, Jagannath S, et al. Pomalidomide alone or in combination with low-dose dexamethasone in relapsed and refractory multiple myeloma: a randomized phase 2 study. Blood. 2014;123:1826\u201332.","journal-title":"Blood"},{"key":"813_CR19","doi-asserted-by":"crossref","first-page":"889","DOI":"10.1111\/bjh.13905","volume":"172","author":"E Rychak","year":"2016","unstructured":"Rychak E, Mendy D, Shi T, Ning Y, Leisten J, Lu L, et al. Pomalidomide in combination with dexamethasone results in synergistic anti-tumour responses in pre-clinical models of lenalidomide-resistant multiple myeloma. Br J Haematol. 2016;172:889\u2013901.","journal-title":"Br J Haematol"},{"key":"813_CR20","doi-asserted-by":"crossref","first-page":"1055","DOI":"10.1016\/S1470-2045(13)70380-2","volume":"14","author":"JS Miguel","year":"2013","unstructured":"Miguel JS, Weisel K, Moreau P, Lacy M, Song K, Delforge M, et al. Pomalidomide plus low-dose dexamethasone versus high-dose dexamethasone alone for patients with relapsed and refractory multiple myeloma (MM-003): a randomised, open-label, phase 3 trial. Lancet Oncol. 2013;14:1055\u201366.","journal-title":"Lancet Oncol"},{"key":"813_CR21","unstructured":"Imnovid (pomalidomide) [summary of product characteristics]. Utrecht, the Netherlands: Celgene Europe B.V.; 2019."},{"key":"813_CR22","unstructured":"Pomalyst (pomalidomide) [package insert]. Summit, NJ: Celgene Corporation; 2019."},{"key":"813_CR23","unstructured":"Darzalex (daratumumab) [package insert]. Horsham, PA: Janssen Biotech, Inc.; 2019."},{"key":"813_CR24","unstructured":"Empliciti (elotozumab) [package insert]. Princeton, NJ: Bristol-Myers Squibb Company; 2019."},{"key":"813_CR25","doi-asserted-by":"crossref","first-page":"781","DOI":"10.1016\/S1470-2045(19)30152-4","volume":"20","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Oriol A, Beksac M, Liberati AM, Galli M, Schjesvold F, et al. Pomalidomide, bortezomib, and dexamethasone for patients with relapsed or refractory multiple myeloma previously treated with lenalidomide (OPTIMISMM): a randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20:781\u201394.","journal-title":"Lancet Oncol"},{"key":"813_CR26","unstructured":"Pomalyst (pomalidomide) [package insert]. Tokyo, Japan: Celgene KK; 2019."},{"key":"813_CR27","doi-asserted-by":"crossref","first-page":"1840","DOI":"10.4049\/jimmunol.1003032","volume":"186","author":"M de Weers","year":"2011","unstructured":"de Weers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing of multiple myeloma and other hematological tumors. J Immunol. 2011;186:1840\u20138.","journal-title":"J Immunol"},{"key":"813_CR28","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1080\/19420862.2015.1007813","volume":"7","author":"MB Overdijk","year":"2015","unstructured":"Overdijk MB, Verploegen S, Bogels M, van Egmond M, Lammerts van Bueren JJ, Mutis T, et al. Antibody-mediated phagocytosis contributes to the anti-tumor activity of the therapeutic antibody daratumumab in lymphoma and multiple myeloma. MAbs. 2015;7:311\u201321.","journal-title":"MAbs"},{"key":"813_CR29","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1182\/blood-2015-12-687749","volume":"128","author":"J Krejcik","year":"2016","unstructured":"Krejcik J, Casneuf T, Nijhof IS, Verbist B, Bald J, Plesner T, et al. Daratumumab depletes CD38+ immune regulatory cells, promotes T-cell expansion, and skews T-cell repertoire in multiple myeloma. Blood. 2016;128:384\u201394.","journal-title":"Blood"},{"key":"813_CR30","doi-asserted-by":"crossref","first-page":"2105","DOI":"10.1182\/bloodadvances.2017006866","volume":"1","author":"T Casneuf","year":"2017","unstructured":"Casneuf T, Xu XS, Adams HC 3rd, Axel AE, Chiu C, Khan I, et al. Effects of daratumumab on natural killer cells and impact on clinical outcomes in relapsed or refractory multiple myeloma. Blood Adv. 2017;1:2105\u201314.","journal-title":"Blood Adv"},{"key":"813_CR31","doi-asserted-by":"crossref","first-page":"974","DOI":"10.1182\/blood-2017-05-785246","volume":"130","author":"A Chari","year":"2017","unstructured":"Chari A, Suvannasankha A, Fay JW, Arnulf B, Kaufman JL, Ifthikharuddin JJ, et al. Daratumumab plus pomalidomide and dexamethasone in relapsed and\/or refractory multiple myeloma. Blood. 2017;130:974\u201381.","journal-title":"Blood"},{"key":"813_CR32","doi-asserted-by":"crossref","first-page":"Abstract 2012","DOI":"10.1182\/blood-2018-99-111554","volume":"132","author":"WE Pierceall","year":"2018","unstructured":"Pierceall WE, Bahlis N, Siegel DS, Schiller GJ, Samaras CJ, Sebag M, et al. Immune profiling of relapsed or refractory multiple myeloma patients treated with pomalidomide and low-dose dexamethasone in combination with daratumumab. Blood. 2018;132:Abstract 2012.","journal-title":"Blood"},{"key":"813_CR33","doi-asserted-by":"crossref","first-page":"501","DOI":"10.1111\/bjh.16213","volume":"188","author":"DS Siegel","year":"2020","unstructured":"Siegel DS, Schiller GJ, Song KW, Agajanian R, Stockerl-Goldstein K, Kaya H, et al. Pomalidomide plus low-dose dexamethasone in relapsed refractory multiple myeloma after lenalidomide treatment failure. Br J Haematol. 2020;188:501\u201310.","journal-title":"Br J Haematol"},{"key":"813_CR34","doi-asserted-by":"crossref","first-page":"Abstract 8006","DOI":"10.1200\/JCO.2019.37.15_suppl.8006","volume":"37","author":"S Lonial","year":"2019","unstructured":"Lonial S, van de Donk NWCJ, Popat R, Zonder JA, Minnema MC, Larsen J, et al. First clinical (phase 1b\/2a) study of iberdomide (CC-220; IBER), a CELMoD, in combination with dexamethasone (DEX) in patients (pts) with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2019;37:Abstract 8006.","journal-title":"J Clin Oncol"},{"key":"813_CR35","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1038\/s41375-019-0620-8","volume":"34","author":"CC Bjorklund","year":"2020","unstructured":"Bjorklund CC, Kang J, Amatangelo M, Polonskaia A, Katz M, Chiu H, et al. Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN. Leukemia.\u00a02020;34:1197\u2013201.","journal-title":"Leukemia"},{"key":"813_CR36","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1470-2045(15)00464-7","volume":"17","author":"MA Dimopoulos","year":"2016","unstructured":"Dimopoulos MA, Moreau P, Palumbo A, Joshua D, Pour L, H\u00e1jek R, et al. Carfilzomib and dexamethasone versus bortezomib and dexamethasone for patients with relapsed or refractory multiple myeloma (ENDEAVOR): a randomised, phase 3, open-label, multicentre study. Lancet Oncol. 2016;17:27\u201338.","journal-title":"Lancet Oncol"},{"key":"813_CR37","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1038\/leu.2016.186","volume":"31","author":"P Moreau","year":"2017","unstructured":"Moreau P, Joshua D, Chng WJ, Palumbo A, Goldschmidt H, H\u00e1jek R, et al. Impact of prior treatment on patients with relapsed multiple myeloma treated with carfilzomib and dexamethasone vs bortezomib and dexamethasone in the phase 3 ENDEAVOR study. Leukemia. 2017;31:115\u201322.","journal-title":"Leukemia"},{"key":"813_CR38","doi-asserted-by":"crossref","first-page":"953","DOI":"10.1016\/S1470-2045(18)30354-1","volume":"19","author":"P Moreau","year":"2018","unstructured":"Moreau P, Mateos MV, Berenson JR, Weisel K, Lazzaro A, Song K, et al. Once weekly versus twice weekly carfilzomib dosing in patients with relapsed and refractory multiple myeloma (A.R.R.O.W.): interim analysis results of a randomised, phase 3 study. Lancet Oncol. 2018;19:953\u201364.","journal-title":"Lancet Oncol"},{"key":"813_CR39","doi-asserted-by":"crossref","first-page":"754","DOI":"10.1056\/NEJMoa1606038","volume":"375","author":"A Palumbo","year":"2016","unstructured":"Palumbo A, Chanan-Khan A, Weisel K, Nooka AK, Masszi T, Beksac M, et al. Daratumumab, bortezomib, and dexamethasone for multiple myeloma. N Engl J Med. 2016;375:754\u201366.","journal-title":"N Engl J Med"},{"key":"813_CR40","first-page":"Abstract 3145","volume":"130","author":"A Spencer","year":"2017","unstructured":"Spencer A, Hungria VTM, Mateos M-V, Nooka A, Estell J, Barreto WG, et al. Daratumumab, bortezomib, and dexamethasone (DVd) versus bortezomib and dexamethasone (Vd) in relapsed or refractory multiple myeloma (RRMM): updated efficacy and safety analysis of Castor. Blood. 2017;130:Abstract 3145.","journal-title":"Blood"},{"key":"813_CR41","doi-asserted-by":"crossref","first-page":"2079","DOI":"10.3324\/haematol.2018.194118","volume":"103","author":"A Spencer","year":"2018","unstructured":"Spencer A, Lentzsch S, Weisel K, Avet-Loiseau H, Mark TM, Spicka I, et al. Daratumumab plus bortezomib and dexamethasone versus bortezomib and dexamethasone in relapsed or refractory multiple myeloma: updated analysis of CASTOR. Haematologica. 2018;103:2079\u201387.","journal-title":"Haematologica"},{"key":"813_CR42","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1056\/NEJMoa1805762","volume":"379","author":"MA Dimopoulos","year":"2018","unstructured":"Dimopoulos MA, Dytfeld D, Grosicki S, Moreau P, Takezako N, Hori M, et al. Elotuzumab plus pomalidomide and dexamethasone for multiple myeloma. N Engl J Med. 2018;379:1811\u201322.","journal-title":"N Engl J Med"},{"key":"813_CR43","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.2217\/fon-2017-0616","volume":"14","author":"PG Richardson","year":"2018","unstructured":"Richardson PG, Attal M, Campana F, Le-Guennec S, Hui AM, Risse ML, et al. Isatuximab plus pomalidomide\/dexamethasone versus pomalidomide\/dexamethasone in relapsed\/refractory multiple myeloma: ICARIA Phase III study design. Future Oncol. 2018;14:1035\u201347.","journal-title":"Future Oncol"},{"key":"813_CR44","doi-asserted-by":"crossref","first-page":"Abstract 8004","DOI":"10.1200\/JCO.2019.37.15_suppl.8004","volume":"37","author":"PG Richardson","year":"2019","unstructured":"Richardson PG, Attal M, Rajkumar SV, San Miguel J, Beksac M, Spicka I, et al. A phase III randomized, open label, multicenter study comparing isatuximab, pomalidomide, and low-dose dexamethasone versus pomalidomide and low-dose dexamethasone in patients with relapsed\/refractory multiple myeloma (RRMM). J Clin Oncol. 2019;37:Abstract 8004.","journal-title":"J Clin Oncol"},{"key":"813_CR45","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1182\/blood.2019000722","volume":"134","author":"A Chari","year":"2019","unstructured":"Chari A, Martinez-Lopez J, Mateos MV, Blad\u00e9 J, Benboubker L, Oriol A, et al. Daratumumab plus carfilzomib and dexamethasone in patients with relapsed or refractory multiple myeloma. Blood. 2019;134:421\u201331.","journal-title":"Blood"},{"key":"813_CR46","first-page":"Abstract LBA","volume":"134","author":"SZ Usmani","year":"2019","unstructured":"Usmani SZ, Quach H, Mateos M-V, Landgren O, Leleu X, Siegel DS, et al. Carfilzomib, dexamethasone, and daratumumab versus carfilzomib and dexamethasone for the treatment of patients with relapsed or refractory multiple myeloma (RRMM): primary analysis results from the randomized, open-label phase 3 study CANDOR (NCT03158688). Blood. 2019;134:Abstract LBA\u20136.","journal-title":"Blood"}],"container-title":["Leukemia"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0813-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0813-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"http:\/\/www.nature.com\/articles\/s41375-020-0813-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,5,20]],"date-time":"2023-05-20T21:40:08Z","timestamp":1684618808000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41375-020-0813-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,5,6]]},"references-count":46,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2020,12]]}},"alternative-id":["813"],"URL":"https:\/\/doi.org\/10.1038\/s41375-020-0813-1","relation":{},"ISSN":["0887-6924","1476-5551"],"issn-type":[{"value":"0887-6924","type":"print"},{"value":"1476-5551","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,5,6]]},"assertion":[{"value":"9 January 2020","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 March 2020","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"20 March 2020","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 May 2020","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"DSS reports speakers bureau for Celgene, a Bristol-Myers Squibb company, Amgen, Takeda, Merck, and Novartis; GJS reports research funding from Celgene, a Bristol-Myers Squibb company; CSS, CS, GT, DQ, MA-R, and BA have nothing to disclose; MS reports consultancy for Celgene, a Bristol-Myers Squibb company, and Janssen; JB reports research funding from Abbvie, Amgen, Acetylon, Bluebird, Bristol-Myers Squibb, Celgene, a Bristol-Myers Squibb company, Constellation, CURIS, Genentech, Glenmark, Janssen, Kesios, Lilly, Novartis, Poseida, Sanofi, Takeda, Teva, Vivolux and consultancy from Takeda, Bristol-Myers Squibb, Karyopharm, CRISPR Therapeutics, Celgene, a Bristol-Myers Squibb company, Kite Pharma Inc, Servier, Janssen, Amgen, BioClinica, Prothena; SG reports speakers bureau for Seattle Genetics; JM reports consultancy for, honoraria from, and speakers bureau for Celgene, a Bristol-Myers Squibb company; KS reports\u00a0honoraria and research funding from Celgene, a Bristol-Myers Squibb company, Janssen, Amgen, Takeda; MB reports consultancy for Celgene, a Bristol-Myers Squibb company; GF reports speakers bureau for Celgene, a Bristol-Myers Squibb company; DR reports consultancy for and honoraria and research funding from Janssen, Celgene, a Bristol-Myers Squibb company, Amgen, Takeda, serving on board of directors or advisory committee for Janssen and Celgene, a Bristol-Myers Squibb company, honoraria and research funding from Merck, and research funding from Otsuka; WEP, WC, and AA report employment with and equity ownership in Bristol-Myers Squibb; FZ reports employment with Bristol-Myers Squibb; NJB reports consultancy for, honoraria and research funding from, and speakers bureau for Celgene, a Bristol-Myers Squibb company, consultancy for Amgen, and speakers bureau, consultancy for, and research funding from Johnson & Johnson.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}